Ryan Cohlhepp, President, COO & Interim CEO at Bicara Therapeutics Inc. (BCAX), sold 17,500 shares at $22.77 ($401K) on 2026-09-08, disclosed to the SEC on 2026-09-10.
Scheduled sale ($401k) by President, COO & Interim CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.77 | 14,058 | $320K | 79.9% |
| 2 | $23.43 | 3,442 | $81K | 20.1% |
| Total | $22.90 avg | 17,500 | $401K | 100% |
| Filing → |
| BCAX | SELL | 2026-05-18 | $254K | — | Filing → |
| BCAX | SELL | 2026-04-17 | $288K | — | Filing → |
| BCAX | SELL | 2026-03-17 | $491K | — | Filing → |